Omnicell Inc (OMCL) 35.90 $OMCL
Uptrend Call Working As Omnicell Stock Rises 24.0% (OMCL)
Comtex SmarTrend(R) - Thu Jul 07, 12:47AM CDT
SmarTrend identified an Uptrend for Omnicell (NASDAQ:OMCL) on April 18th, 2016 at $28.34. In approximately 3 months, Omnicell has returned 23.96% as of today's recent price of $35.13.
OMCL: 35.90 (+0.79)
Omnicell Has Returned 21.1% Since SmarTrend Recommendation (OMCL)
Comtex SmarTrend(R) - Wed Jun 29, 1:53PM CDT
SmarTrend identified an Uptrend for Omnicell (NASDAQ:OMCL) on April 18th, 2016 at $28.34. In approximately 2 months, Omnicell has returned 21.14% as of today's recent price of $34.33.
OMCL: 35.90 (+0.79)
Omnicell Grows amid Weak Margins, Hospital Spending Woes
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 8:57AM CDT
On Jun 1, 2016, we issued an updated research report on Omnicell, Inc. (OMCL).
MDSO: 48.17 (+1.14), DRAD: 5.45 (+0.19), OMCL: 35.90 (+0.79), ATHN: 140.27 (+0.35)
Omnicell (OMCL) Q1 Earnings Top Estimates, Margins Drag
Zacks Equity Research - Zacks Investment Research - Mon May 02, 10:05AM CDT
Omnicell, Inc. (OMCL) reported first-quarter 2016 adjusted earnings per share (EPS) of 30 cents, reflecting year-over-year improvement of 57.9%.
MDSO: 48.17 (+1.14), QSII: 12.44 (+0.38), CPSI: 40.68 (+0.95), OMCL: 35.90 (+0.79)
Deutsche Bank 41st Annual Health Care Conference
PR Newswire - Fri Apr 29, 7:07AM CDT
Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication and supply management solutions and analytics software for health care facilities, today announced they will present at the Deutsche Bank 41st annual Health Care Conference at the InterContinental Boston Hotel, Boston, MA.
DB: 12.97 (+0.37), OMCL: 35.90 (+0.79)
Omnicell reports 1Q loss
Automated Insights - Thu Apr 28, 4:47PM CDT
MOUNTAIN VIEW, Calif. (AP) _ Omnicell Inc. (OMCL) on Thursday reported a first-quarter loss of $378,000, after reporting a profit in the same period a year earlier.
OMCL: 35.90 (+0.79)
UnityPoint Health® Selects Omnicell Medication Automation, Central Pharmacy and Analytics Solutions to Enhance Patient Safety and Efficiency
PR Newswire - Wed Apr 27, 7:00AM CDT
Omnicell, Inc. (NASDAQ: OMCL) today announced that UnityPoint Health® has awarded the Company a 10-year sole source contract as its provider of medication automation, central pharmacy automation and analytics software across 15 of its facilities. UnityPoint Health expects Omnicell's solutions to advance the highest standards of patient safety and security while optimizing pharmacist, nurse and anesthesiologist workflows. Two benefits offered by Omnicell are the Omnicell Unity enterprise platform, which gives health systems enhanced visibility across multiple Omnicell systems, and interoperability with the Epic electronic health record (EHR) system, which is used by UnityPoint Health. Installation is expected to be completed by the end of the year.
OMCL: 35.90 (+0.79)
Omnicell to Release First Quarter 2016 Earnings Results on April 28th
PR Newswire - Thu Apr 21, 7:00AM CDT
Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication and supply management solutions and analytics software for healthcare facilities, will hold a conference call Thursday, April 28, 2016, to discuss the Company's First Quarter 2016 financial results.
OMCL: 35.90 (+0.79)
UW Health Adds New IV Automation Capabilities and Solutions to Enhance Hybrid Drug Distribution Process
PR Newswire - Wed Apr 06, 7:00AM CDT
Omnicell, Inc. (NASDAQ: OMCL) is pleased to report that UW Health, the system associated with the University of Wisconsin-Madison, is adding the i.v.STATION ONCO(TM), which provides robotic sterile compounding of oncology admixtures, to their pharmacy automation solutions. UW Health selected the Aesynt product, now part of Omnicell's product portfolio, for use in the drug distribution process at their main University Hospital as well as in three additional facilities in their health system. In addition, the hospital is updating their existing ROBOT-Rx® automated medication dispensing robot and upgrading their AcuDose-Rx® automated dispensing cabinets. These and other products from Aesynt have recently been added to the Omnicell portfolio, expanding Omnicell's ability to support all key pharmacy distribution models, described as follows:
OMCL: 35.90 (+0.79)
Omnicell Announces New Guided Packing Software Designed to Increase Packing Accuracy of SureMed Multimed Blister Cards which Improve Patient Adherence
PR Newswire - Thu Mar 31, 10:00AM CDT
Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication and supply management solutions and adherence tools to health care systems and pharmacies, today announced general availability of its latest medication adherence solution, the SureMed(TM) by Omnicell® Guided Packing software. This cloud-based software is designed to increase pharmacists' accuracy in filling SureMed multiple medication blister cards, which can improve medication adherence for patients on complex medication regimens. At launch, the software will interface with QS1, one of the most widely used pharmacy information systems (PIS), and is planned to integrate with additional systems later this year.
OMCL: 35.90 (+0.79)
Add Omnicell (OMCL) to Your Investment Portfolio: Here's Why
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 3:00PM CDT
On Mar 29, 2016, we issued an updated research report on Omnicell, Inc. (OMCL).
MDRX: 13.87 (+0.33), NVTA: 9.04 (+0.50), OMCL: 35.90 (+0.79), ATHN: 140.27 (+0.35)
Omnicell Announces Organizational Realignment to Increase Strategic and Operational Focus
PR Newswire - Mon Mar 21, 3:01PM CDT
Omnicell, Inc., (NASDAQ: OMCL), today announced it is realigning its organization to continue its growth strategy of offering differentiated products, expanding into new markets and increasing its presence through acquisitions. Over the past year, Omnicell has expanded its solutions and market reach through a series of acquisitions and new product announcements. The new organization will assure focus at the highest levels of the company on the successful integration of the acquisitions while simultaneously sustaining the momentum of new product innovation and expansion into new markets.
OMCL: 35.90 (+0.79)
Omnicell presents the pro forma financial information related to its acquisition of Aesynt
PR Newswire - Thu Mar 17, 3:15PM CDT
Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication and supply management solutions to healthcare systems, today issued a press release presenting the pro forma financial information related to its recent acquisition of Aesynt Holding Coöperatief U.A. ("Aesynt"
.
OMCL: 35.90 (+0.79)
Omnicell Launches Pharmacy Locator to Connect Consumers with Pharmacies Supporting Medication Adherence Technology
PR Newswire - Wed Mar 16, 7:00AM CDT
Omnicell, Inc., (NASDAQ: OMCL), today announced the availability of the web-based Find-A-Pharmacy tool, which helps connect consumers and their families with pharmacists committed to improving the health of their patients through better medication adherence. By offering SureMed® by Omnicell® multiple medication adherence blister cards, pharmacists are helping patients greatly reduce the complexities of managing and taking multiple medications daily. Currently over one million people use SureMed to help successfully remain in compliance with physician-recommended therapy. The SureMed blister cards organize complex medication regimens by time of day and day of the week, making it easy for patients to know what to take and when.
OMCL: 35.90 (+0.79)
Omnicell Q4 Earnings, Revenues Rise Y/Y; Aesynt Buyout Over
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 11:30AM CST
Omnicell's (OMCL) outperformance on the revenue front is encouraging. However, the company's performance on the bottom-line front remains mixed.
LMAT: 13.70 (+0.14), VASC: 43.51 (+1.03), OMCL: 35.90 (+0.79), HRC: 51.37 (+0.57)
athenahealth Crushes Q4 Earnings Estimate, Revenues Meet
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 10:30AM CST
athenahealth Inc. (ATHN) reported earnings of 45 cents per share in the fourth quarter of 2015, well ahead of the Zacks Consensus Estimate of 16 cents.
STRM: 1.20 (+0.01), CPSI: 40.68 (+0.95), OMCL: 35.90 (+0.79), ATHN: 140.27 (+0.35)
Omnicell tops Street 4Q forecasts
Automated Insights - Thu Feb 04, 3:59PM CST
MOUNTAIN VIEW, Calif. (AP) _ Omnicell Inc. (OMCL) on Thursday reported fourth-quarter earnings of $7.7 million.
OMCL: 35.90 (+0.79)
Uptrend Call Working As Omnicell Stock Rises 24.0% (OMCL)
Comtex SmarTrend(R) - Thu Jul 07, 12:47AM CDT
SmarTrend identified an Uptrend for Omnicell (NASDAQ:OMCL) on April 18th, 2016 at $28.34. In approximately 3 months, Omnicell has returned 23.96% as of today's recent price of $35.13.
OMCL: 35.90 (+0.79)
Omnicell Has Returned 21.1% Since SmarTrend Recommendation (OMCL)
Comtex SmarTrend(R) - Wed Jun 29, 1:53PM CDT
SmarTrend identified an Uptrend for Omnicell (NASDAQ:OMCL) on April 18th, 2016 at $28.34. In approximately 2 months, Omnicell has returned 21.14% as of today's recent price of $34.33.
OMCL: 35.90 (+0.79)
Omnicell Grows amid Weak Margins, Hospital Spending Woes
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 8:57AM CDT
On Jun 1, 2016, we issued an updated research report on Omnicell, Inc. (OMCL).
MDSO: 48.17 (+1.14), DRAD: 5.45 (+0.19), OMCL: 35.90 (+0.79), ATHN: 140.27 (+0.35)
Omnicell (OMCL) Q1 Earnings Top Estimates, Margins Drag
Zacks Equity Research - Zacks Investment Research - Mon May 02, 10:05AM CDT
Omnicell, Inc. (OMCL) reported first-quarter 2016 adjusted earnings per share (EPS) of 30 cents, reflecting year-over-year improvement of 57.9%.
MDSO: 48.17 (+1.14), QSII: 12.44 (+0.38), CPSI: 40.68 (+0.95), OMCL: 35.90 (+0.79)
Deutsche Bank 41st Annual Health Care Conference
PR Newswire - Fri Apr 29, 7:07AM CDT
Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication and supply management solutions and analytics software for health care facilities, today announced they will present at the Deutsche Bank 41st annual Health Care Conference at the InterContinental Boston Hotel, Boston, MA.
DB: 12.97 (+0.37), OMCL: 35.90 (+0.79)
Omnicell reports 1Q loss
Automated Insights - Thu Apr 28, 4:47PM CDT
MOUNTAIN VIEW, Calif. (AP) _ Omnicell Inc. (OMCL) on Thursday reported a first-quarter loss of $378,000, after reporting a profit in the same period a year earlier.
OMCL: 35.90 (+0.79)
UnityPoint Health® Selects Omnicell Medication Automation, Central Pharmacy and Analytics Solutions to Enhance Patient Safety and Efficiency
PR Newswire - Wed Apr 27, 7:00AM CDT
Omnicell, Inc. (NASDAQ: OMCL) today announced that UnityPoint Health® has awarded the Company a 10-year sole source contract as its provider of medication automation, central pharmacy automation and analytics software across 15 of its facilities. UnityPoint Health expects Omnicell's solutions to advance the highest standards of patient safety and security while optimizing pharmacist, nurse and anesthesiologist workflows. Two benefits offered by Omnicell are the Omnicell Unity enterprise platform, which gives health systems enhanced visibility across multiple Omnicell systems, and interoperability with the Epic electronic health record (EHR) system, which is used by UnityPoint Health. Installation is expected to be completed by the end of the year.
OMCL: 35.90 (+0.79)
Omnicell to Release First Quarter 2016 Earnings Results on April 28th
PR Newswire - Thu Apr 21, 7:00AM CDT
Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication and supply management solutions and analytics software for healthcare facilities, will hold a conference call Thursday, April 28, 2016, to discuss the Company's First Quarter 2016 financial results.
OMCL: 35.90 (+0.79)
UW Health Adds New IV Automation Capabilities and Solutions to Enhance Hybrid Drug Distribution Process
PR Newswire - Wed Apr 06, 7:00AM CDT
Omnicell, Inc. (NASDAQ: OMCL) is pleased to report that UW Health, the system associated with the University of Wisconsin-Madison, is adding the i.v.STATION ONCO(TM), which provides robotic sterile compounding of oncology admixtures, to their pharmacy automation solutions. UW Health selected the Aesynt product, now part of Omnicell's product portfolio, for use in the drug distribution process at their main University Hospital as well as in three additional facilities in their health system. In addition, the hospital is updating their existing ROBOT-Rx® automated medication dispensing robot and upgrading their AcuDose-Rx® automated dispensing cabinets. These and other products from Aesynt have recently been added to the Omnicell portfolio, expanding Omnicell's ability to support all key pharmacy distribution models, described as follows:
OMCL: 35.90 (+0.79)
Omnicell Announces New Guided Packing Software Designed to Increase Packing Accuracy of SureMed Multimed Blister Cards which Improve Patient Adherence
PR Newswire - Thu Mar 31, 10:00AM CDT
Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication and supply management solutions and adherence tools to health care systems and pharmacies, today announced general availability of its latest medication adherence solution, the SureMed(TM) by Omnicell® Guided Packing software. This cloud-based software is designed to increase pharmacists' accuracy in filling SureMed multiple medication blister cards, which can improve medication adherence for patients on complex medication regimens. At launch, the software will interface with QS1, one of the most widely used pharmacy information systems (PIS), and is planned to integrate with additional systems later this year.
OMCL: 35.90 (+0.79)
Add Omnicell (OMCL) to Your Investment Portfolio: Here's Why
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 3:00PM CDT
On Mar 29, 2016, we issued an updated research report on Omnicell, Inc. (OMCL).
MDRX: 13.87 (+0.33), NVTA: 9.04 (+0.50), OMCL: 35.90 (+0.79), ATHN: 140.27 (+0.35)
Omnicell Announces Organizational Realignment to Increase Strategic and Operational Focus
PR Newswire - Mon Mar 21, 3:01PM CDT
Omnicell, Inc., (NASDAQ: OMCL), today announced it is realigning its organization to continue its growth strategy of offering differentiated products, expanding into new markets and increasing its presence through acquisitions. Over the past year, Omnicell has expanded its solutions and market reach through a series of acquisitions and new product announcements. The new organization will assure focus at the highest levels of the company on the successful integration of the acquisitions while simultaneously sustaining the momentum of new product innovation and expansion into new markets.
OMCL: 35.90 (+0.79)
Omnicell presents the pro forma financial information related to its acquisition of Aesynt
PR Newswire - Thu Mar 17, 3:15PM CDT
Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication and supply management solutions to healthcare systems, today issued a press release presenting the pro forma financial information related to its recent acquisition of Aesynt Holding Coöperatief U.A. ("Aesynt"
. OMCL: 35.90 (+0.79)
Omnicell Launches Pharmacy Locator to Connect Consumers with Pharmacies Supporting Medication Adherence Technology
PR Newswire - Wed Mar 16, 7:00AM CDT
Omnicell, Inc., (NASDAQ: OMCL), today announced the availability of the web-based Find-A-Pharmacy tool, which helps connect consumers and their families with pharmacists committed to improving the health of their patients through better medication adherence. By offering SureMed® by Omnicell® multiple medication adherence blister cards, pharmacists are helping patients greatly reduce the complexities of managing and taking multiple medications daily. Currently over one million people use SureMed to help successfully remain in compliance with physician-recommended therapy. The SureMed blister cards organize complex medication regimens by time of day and day of the week, making it easy for patients to know what to take and when.
OMCL: 35.90 (+0.79)
Omnicell Q4 Earnings, Revenues Rise Y/Y; Aesynt Buyout Over
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 11:30AM CST
Omnicell's (OMCL) outperformance on the revenue front is encouraging. However, the company's performance on the bottom-line front remains mixed.
LMAT: 13.70 (+0.14), VASC: 43.51 (+1.03), OMCL: 35.90 (+0.79), HRC: 51.37 (+0.57)
athenahealth Crushes Q4 Earnings Estimate, Revenues Meet
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 10:30AM CST
athenahealth Inc. (ATHN) reported earnings of 45 cents per share in the fourth quarter of 2015, well ahead of the Zacks Consensus Estimate of 16 cents.
STRM: 1.20 (+0.01), CPSI: 40.68 (+0.95), OMCL: 35.90 (+0.79), ATHN: 140.27 (+0.35)
Omnicell tops Street 4Q forecasts
Automated Insights - Thu Feb 04, 3:59PM CST
MOUNTAIN VIEW, Calif. (AP) _ Omnicell Inc. (OMCL) on Thursday reported fourth-quarter earnings of $7.7 million.
OMCL: 35.90 (+0.79)
